SE462364B - Anvaendning av gamma-interferon foer beredning av ett preparat foer behandling av vaskulaer stenos - Google Patents

Anvaendning av gamma-interferon foer beredning av ett preparat foer behandling av vaskulaer stenos

Info

Publication number
SE462364B
SE462364B SE8803472A SE8803472A SE462364B SE 462364 B SE462364 B SE 462364B SE 8803472 A SE8803472 A SE 8803472A SE 8803472 A SE8803472 A SE 8803472A SE 462364 B SE462364 B SE 462364B
Authority
SE
Sweden
Prior art keywords
cells
gamma interferon
smooth muscle
gamma
interferon
Prior art date
Application number
SE8803472A
Other languages
English (en)
Swedish (sv)
Other versions
SE8803472D0 (sv
Inventor
Goeran Hansson
Jan Holm
Lena Jonasson
Original Assignee
Goeran Hansson
Jan Holm
Lena Jonasson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Goeran Hansson, Jan Holm, Lena Jonasson filed Critical Goeran Hansson
Priority to SE8803472A priority Critical patent/SE462364B/sv
Publication of SE8803472D0 publication Critical patent/SE8803472D0/xx
Priority to US07/671,786 priority patent/US5208019A/en
Priority to JP1510051A priority patent/JP2895896B2/ja
Priority to HU895542A priority patent/HU206988B/hu
Priority to AU43051/89A priority patent/AU623181B2/en
Priority to AT89850317T priority patent/ATE86869T1/de
Priority to IL9179689A priority patent/IL91796A/en
Priority to PCT/SE1989/000520 priority patent/WO1990003189A1/en
Priority to KR1019900701144A priority patent/KR0137017B1/ko
Priority to DE89850317T priority patent/DE68905438T2/de
Priority to EP89850317A priority patent/EP0367735B1/de
Priority to NZ230816A priority patent/NZ230816A/en
Priority to DD89333072A priority patent/DD288094A5/de
Priority to PT91863A priority patent/PT91863B/pt
Priority to CA000614859A priority patent/CA1338722C/en
Priority to IE312389A priority patent/IE63874B1/en
Priority to PH39308A priority patent/PH26293A/en
Publication of SE462364B publication Critical patent/SE462364B/sv
Priority to DK199100562A priority patent/DK174523B1/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Radiation-Therapy Devices (AREA)
SE8803472A 1988-09-30 1988-09-30 Anvaendning av gamma-interferon foer beredning av ett preparat foer behandling av vaskulaer stenos SE462364B (sv)

Priority Applications (18)

Application Number Priority Date Filing Date Title
SE8803472A SE462364B (sv) 1988-09-30 1988-09-30 Anvaendning av gamma-interferon foer beredning av ett preparat foer behandling av vaskulaer stenos
JP1510051A JP2895896B2 (ja) 1988-09-30 1989-09-27 脈管狭窄の治療におけるγ―インターフェロンの使用
KR1019900701144A KR0137017B1 (ko) 1988-09-30 1989-09-27 감마-인터페론을 이용한 혈관 협착증의 치료방법
EP89850317A EP0367735B1 (de) 1988-09-30 1989-09-27 Verwendung von Interferon-gamma in pharmazeutischen Zubereitungen zur Behandlung von Gefässstenose
HU895542A HU206988B (en) 1988-09-30 1989-09-27 Process for producing pharmaceutical composition comprising gamma-interferon as active ingredient
AU43051/89A AU623181B2 (en) 1988-09-30 1989-09-27 Use of gamma-interferon for the treatment of vascular stenosis
AT89850317T ATE86869T1 (de) 1988-09-30 1989-09-27 Verwendung von interferon-gamma in pharmazeutischen zubereitungen zur behandlung von gefaessstenose.
IL9179689A IL91796A (en) 1988-09-30 1989-09-27 Pharmacological preparations containing gamma interferon
PCT/SE1989/000520 WO1990003189A1 (en) 1988-09-30 1989-09-27 Use of gamma-interferon for the treatment of vascular stenosis
US07/671,786 US5208019A (en) 1988-09-30 1989-09-27 Use of gamma-interferon for the treatment of vascular stenosis
DE89850317T DE68905438T2 (de) 1988-09-30 1989-09-27 Verwendung von Interferon-gamma in pharmazeutischen Zubereitungen zur Behandlung von Gefässstenose.
NZ230816A NZ230816A (en) 1988-09-30 1989-09-28 Gamma interferon, treatment of vascular stenosis
DD89333072A DD288094A5 (de) 1988-09-30 1989-09-28 Verwendung von gamma-interferon zur behandlung von gefaessverengungen
PT91863A PT91863B (pt) 1988-09-30 1989-09-29 Processo de preparacao de uma preparacao farmaceutica a base de gama-interferao
CA000614859A CA1338722C (en) 1988-09-30 1989-09-29 Gamma-interferon for the treatment of vascular stenosis
IE312389A IE63874B1 (en) 1988-09-30 1989-09-29 Use of gamma-interferon for the treatment of vascular stenosis
PH39308A PH26293A (en) 1988-09-30 1989-09-29 Use of gamma-interferon for the treatment of vascular stenosis
DK199100562A DK174523B1 (da) 1988-09-30 1991-03-27 Anvendelse af gamma-interferon til fremstilling af et lægemiddel til behandling af vasculær stenosis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE8803472A SE462364B (sv) 1988-09-30 1988-09-30 Anvaendning av gamma-interferon foer beredning av ett preparat foer behandling av vaskulaer stenos

Publications (2)

Publication Number Publication Date
SE8803472D0 SE8803472D0 (sv) 1988-09-30
SE462364B true SE462364B (sv) 1990-06-18

Family

ID=20373494

Family Applications (1)

Application Number Title Priority Date Filing Date
SE8803472A SE462364B (sv) 1988-09-30 1988-09-30 Anvaendning av gamma-interferon foer beredning av ett preparat foer behandling av vaskulaer stenos

Country Status (18)

Country Link
US (1) US5208019A (de)
EP (1) EP0367735B1 (de)
JP (1) JP2895896B2 (de)
KR (1) KR0137017B1 (de)
AT (1) ATE86869T1 (de)
AU (1) AU623181B2 (de)
CA (1) CA1338722C (de)
DD (1) DD288094A5 (de)
DE (1) DE68905438T2 (de)
DK (1) DK174523B1 (de)
HU (1) HU206988B (de)
IE (1) IE63874B1 (de)
IL (1) IL91796A (de)
NZ (1) NZ230816A (de)
PH (1) PH26293A (de)
PT (1) PT91863B (de)
SE (1) SE462364B (de)
WO (1) WO1990003189A1 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811447A (en) * 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
EP0671954A1 (de) * 1992-02-05 1995-09-20 Thomas Jefferson University Interferon-gentherapie für die behandlung von gefässkrankheiten
US6251920B1 (en) 1993-05-13 2001-06-26 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US6395494B1 (en) * 1993-05-13 2002-05-28 Neorx Corporation Method to determine TGF-β
US5770609A (en) * 1993-01-28 1998-06-23 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US6306421B1 (en) 1992-09-25 2001-10-23 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5957972A (en) * 1992-09-29 1999-09-28 Arizona Board Of Regents On Behalf Of The University Of Arizona Implants possessing a surface of endothelial cells genetically-modified to inhibit intimal thickening
PT690726E (pt) * 1993-01-07 2002-05-31 Univ Jefferson Inibicao anti-sentido de c-myc para modular a proliferacao de celulas do musculo liso
US5595722A (en) * 1993-01-28 1997-01-21 Neorx Corporation Method for identifying an agent which increases TGF-beta levels
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5981568A (en) 1993-01-28 1999-11-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6663881B2 (en) 1993-01-28 2003-12-16 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6197789B1 (en) 1995-06-07 2001-03-06 Neorx Corporation Prevention and treatment of cardiovascular pathologies with tamoxifen analogues
DE69435137D1 (de) * 1993-05-13 2008-10-16 Poniard Pharmaceuticals Inc Prävention und behandlung von pathologien, die mit einer abnormalen proliferationglatter muskelzellen verbunden sind
US6323184B1 (en) 1993-10-15 2001-11-27 Thomas Jefferson University Arteriovenous and venous graft treatments: methods and compositions
US6133242A (en) * 1993-10-15 2000-10-17 Thomas Jefferson Univerisity Inhibition of extracellular matrix synthesis by antisense compounds directed to nuclear proto-oncogenes
US5449679A (en) * 1994-07-29 1995-09-12 Leonard; Robert J. Process and products for reducing biological fluid levels of a lipid soluble waste
US5665591A (en) * 1994-12-06 1997-09-09 Trustees Of Boston University Regulation of smooth muscle cell proliferation
US7611533B2 (en) * 1995-06-07 2009-11-03 Cook Incorporated Coated implantable medical device
CA2210622A1 (en) * 1995-11-17 1997-05-29 Toray Industries, Inc. An agent protecting endothelial cells
US5681558A (en) * 1995-11-30 1997-10-28 Berlex Laboratories, Inc. Method of using beta-interferons to treat restenosis
ES2314786T3 (es) 1998-04-02 2009-03-16 Genentech, Inc. Uso de interferon gamma para el tratamiento de la hipertrofia cardiaca.
US7524826B2 (en) * 2000-04-14 2009-04-28 Mcmaster University And Hamilton Health Sciences Corporation Method of inhibiting the generation of active thrombin on the surface of a cell within an atherosclerotic plaque
AU2002310922A1 (en) * 2001-05-04 2002-11-18 Institute Of Molecular And Cell Biology Interferons in the treatment of ischemia
JP4896745B2 (ja) 2004-02-02 2012-03-14 アンブレツクス・インコーポレイテツド 修飾されたヒトインターフェロンポリペプチドおよびこれらの使用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE11014T1 (de) * 1981-07-14 1985-01-15 Efamol Limited Pharmazeutische und diaetetische zusammensetzung zur erhoehung der serie-l-pg-produktion.
US5096705A (en) * 1981-10-19 1992-03-17 Genentech, Inc. Human immune interferon
US4454115A (en) * 1981-10-23 1984-06-12 Wisconsin Alumni Research Foundation Method of reducing the level of low density lipoproteins in the serum of a patient
US4483849A (en) * 1983-01-07 1984-11-20 Carter William A Stabilization and purification of interferon with propylene glycol, resulting in a non-toxic product
JPS6069037A (ja) * 1983-09-26 1985-04-19 Sunstar Inc エリテマト−デス治療用外用剤
US4680175A (en) * 1984-02-07 1987-07-14 Interferon Sciences, Inc. Interferon administration vehicles
US4605555A (en) * 1984-09-20 1986-08-12 Sun Star Kabushiki Kaisha Composition and method for treating keratosic disorder of skin and mucosa
US4946674A (en) * 1984-10-05 1990-08-07 Bioferon Biochemische Substanzen Gmbh & Co. Process for treatment of rheumatic diseases
IL78444A (en) * 1986-04-08 1992-05-25 Yeda Res & Dev Human gamma interferon-specific receptor protein,antibody against said protein,and compositions containing said protein and antibody
US5026544A (en) * 1988-02-16 1991-06-25 Board Of Reagents, The University Of Texas System Methods and compositions for inhibiting the growth of neoplastic cells

Also Published As

Publication number Publication date
SE8803472D0 (sv) 1988-09-30
DE68905438T2 (de) 1993-09-30
HU206988B (en) 1993-03-01
AU623181B2 (en) 1992-05-07
EP0367735B1 (de) 1993-03-17
DE68905438D1 (de) 1993-04-22
JPH04500966A (ja) 1992-02-20
WO1990003189A1 (en) 1990-04-05
ATE86869T1 (de) 1993-04-15
AU4305189A (en) 1990-04-18
PH26293A (en) 1992-04-10
DK56291D0 (da) 1991-03-27
US5208019A (en) 1993-05-04
PT91863B (pt) 1995-05-31
KR0137017B1 (ko) 1998-04-25
JP2895896B2 (ja) 1999-05-24
DD288094A5 (de) 1991-03-21
NZ230816A (en) 1997-06-24
HU895542D0 (en) 1991-10-28
PT91863A (pt) 1990-03-30
CA1338722C (en) 1996-11-19
EP0367735A1 (de) 1990-05-09
KR900701308A (ko) 1990-12-01
IL91796A (en) 1994-10-07
IL91796A0 (en) 1990-06-10
IE63874B1 (en) 1995-06-14
DK174523B1 (da) 2003-05-12
DK56291A (da) 1991-05-24
HUT57063A (en) 1991-11-28
IE893123L (en) 1990-03-30

Similar Documents

Publication Publication Date Title
SE462364B (sv) Anvaendning av gamma-interferon foer beredning av ett preparat foer behandling av vaskulaer stenos
Hansson et al. Gamma-interferon regulates vascular smooth muscle proliferation and Ia antigen expression in vivo and in vitro.
JP3854307B2 (ja) 細胞外マトリックスの蓄積を防止するためのトランスフォーミング増殖因子βの阻害
US5318957A (en) Method of stimulating angiogenesis
Murthy et al. The synthetic GLP-I receptor agonist, exenatide, reduces intimal hyperplasia in insulin resistant rats
AU5263998A (en) Method for treating symptoms of diabetes
Hruby et al. Antiserum against tumor necrosis factor-alpha and a protease inhibitor reduce immune glomerular injury
JP2009024026A (ja) 血管形成的に有効なｆｇｆ−２の単位用量および使用方法
Ahrén et al. Effects of cholecystokinin (CCK)-8, CCK-33, and gastric inhibitory polypeptide (GIP) on basal and meal-stimulated pancreatic hormone secretion in man
US20070299002A1 (en) Alpha1-Acid Glycoprotein for the Treatment of Diabetes
Huynh et al. Adiponectin has a pivotal role in the cardioprotective effect of CP‐3 (iv), a selective CD36 azapeptide ligand, after transient coronary artery occlusion in mice
EP1358888A1 (de) Das humane Peptidantibiotikum LL-37/hCAP-18 ist ein Angiogeneseinduktor
US6060449A (en) Neovascularization inhibitor containing tissue factor pathway inhibitor
EP0408677B1 (de) Steigerung der c1-inhibitorkonzentrationen mittels interferon gamma allein oder in kombination mit interleukin-6
CA2100876A1 (en) Anti-growth factor antibodies in the treatment of vascular stenosis
JP2008031179A (ja) β−インターフェロンを使用して再狭窄を治療する方法
JPH02209812A (ja) 乾癬治療用医薬組成物
US20060275303A1 (en) Modulating angiogenesis using LL-37/HCAP-18
JPH03500660A (ja) 血管閉塞抑制剤
JPS60501558A (ja) インタ−フエロン感受性疾病の治療方法およびγ−インタ−フエロン含有製剤の製造方法および装置
Kadowaki et al. The effect of hypercholesterolemia on early atherosclerotic lesions initiated by fibrinopeptide B
JPH09124506A (ja) 組織因子凝固系インヒビター含有動脈硬化治療剤
KHIDER et al. NEUROSTEROID, NATURAL AND ANABOLIC STEROIDS: PHYSIOLOGICAL, IMMUNOLOGICAL AND HISTOPATHOLOGICAL STUDY ON HYPERLIPIDAEMIC ALBINO RATS
Casato et al. Idiopathic Mixed Cryoglobulinemia: A New Therapeutic Approach with Alpha Interferon
Pepys et al. Role of the acute phase response in the Shwartzman phenomenon.

Legal Events

Date Code Title Description
NAL Patent in force

Ref document number: 8803472-3

Format of ref document f/p: F

NUG Patent has lapsed

Ref document number: 8803472-3

Format of ref document f/p: F